Belgian biotechnology company ViroVet partnered with researchers at The Pirbright Institute in 2019 to develop and test the first antiviral drugs that act against African swine fever (ASF). In the abscence of a vaccine, antiviral drugs will provide an alternative control method which can help limit clinical signs in pigs and lower virus replication. This will reduce the spread of disease and help to contain outbreaks, ultimately reducing the number of pigs lost to this deadly viral infection.